News

Industry News

View All » Industry News RSS Feed
Endo Pharmaceuticals Recalls Robaxin Due to Incorrect Dosing Label

Endo Pharmaceuticals Recalls Robaxin Due to Incorrect Dosing Label

Endo Pharmaceuticals is voluntarily recalling two lots of Robaxin (methocarbamol tablets) due to incorrect daily dosing information on the label, which misstates the daily dose as “two to four tablets four times a day,” which could result in 16 tablets, rather than the correct dosage of “two tablets three times daily,” which results in 6 tablets.

Read More »
DEA Reschedules Epidiolex, a Marijuana-Derived Drug

DEA Reschedules Epidiolex, a Marijuana-Derived Drug

The Drug Enforcement Agency (DEA) announced that Epidiolex (cannabidiol) oral solution, a drug derived from marijuana, will be rescheduled from a schedule I drug to a schedule V drug.

Read More »
FDA Approves Ajovy for the Preventive Treatment of Migraines

FDA Approves Ajovy for the Preventive Treatment of Migraines

The FDA has approved Ajovy (fremanezumab-vfrm) injections for the preventive treatment of migraines. Ajovy will be available in 225 mg monthly doses, or 675 mg quarterly doses.

Read More »
FDA Approves New Dosage of Buprenorphine and Naloxone Film for Opioid Dependence

FDA Approves New Dosage of Buprenorphine and Naloxone Film for Opioid Dependence

The FDA has approved Cassipa (buprenorphine and naloxone) sublingual film for the maintenance treatment of opioid dependence. While similar sublingual films – which dissolve under the tongue – already exist for the treatment of opioid dependence, Cassipa introduces a new dosage strength of 16 mg/4mg.

Read More »